Skip navigation
Universidade de Brasília
Please use this identifier to cite or link to this item: http://repositorio.unb.br/handle/10482/45003
Files in This Item:
There are no files associated with this item.
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSakamoto, Luis Henrique Toshihiro-
dc.contributor.authorAndrade, Rosângela Vieira de-
dc.contributor.authorFelipe, Maria Sueli Soares-
dc.contributor.authorMotoyama, Andrea Barretto-
dc.contributor.authorPittella-Silva, Fabio-
dc.date.accessioned2022-10-06T13:08:29Z-
dc.date.available2022-10-06T13:08:29Z-
dc.date.issued2014-04-
dc.identifier.citationSAKAMOTO, Luis Henrique Toshihiro et al. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leukemia Research, v. 38, n. 4, p. 496-502, abr. 2014. DOI: https://doi.org/10.1016/j.leukres.2014.01.013.pt_BR
dc.identifier.urihttps://repositorio.unb.br/handle/10482/45003-
dc.language.isoInglêspt_BR
dc.publisherElsevierpt_BR
dc.rightsAcesso Restritopt_BR
dc.titleSMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factorpt_BR
dc.typeArtigopt_BR
dc.subject.keywordProteínaspt_BR
dc.subject.keywordLeucemia linfoblástica aguda (LLA)pt_BR
dc.subject.keywordInfânciapt_BR
dc.subject.keywordPrognósticopt_BR
dc.subject.keywordLisinapt_BR
dc.subject.keywordMetiltransferasept_BR
dc.subject.keywordExpressão gênicapt_BR
dc.identifier.doihttps://doi.org/10.1016/j.leukres.2014.01.013pt_BR
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0145212614000319?via%3Dihubpt_BR
dc.description.abstract1Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. In this study, we performed quantitative real time PCR to compare the expression of SMYD2 in 83 pediatric ALL patients and non-neoplastic bone marrow samples (BMS). The study revealed that SMYD2 expression is altered in ALL BMS and its high expression was correlated with a bad prognosis. Moreover, we also revealed that SMYD2 expression level significantly decreases in patients that respond to chemotherapy treatment.pt_BR
dc.contributor.affiliationUniversidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Patologia Molecular do Câncerpt_BR
dc.contributor.affiliationUniversidade Católica de Brasília, Laboratório de Ciências Genômicas e Biotecnologia Molecularpt_BR
dc.contributor.affiliationUniversidade de Brasília, Departamento de Biologia Celularpt_BR
dc.contributor.affiliationHospital Infantil José Alencar de Brasíliapt_BR
Appears in Collections:Artigos publicados em periódicos e afins
UnB - Professores Eméritos

Show simple item record " class="statisticsLink btn btn-primary" href="/handle/10482/45003/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.